BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1449@pharmaconomics
DTSTAMP:20260707T051207Z
DTSTART;VALUE=DATE:20260328
DTEND;VALUE=DATE:20260329
SUMMARY:IFRX AdCom — vilobelimab
DESCRIPTION:An FDA advisory committee reviews vilobelimab for pyoderma gangrenosum (PG) around Mar 28\, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1708688/000121390026031549/ea028182101ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/1449
URL:https://www.pharmaconomics.com/e/1449
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IFRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR